

Resource Summary Report

Generated by PRECISE-TBI on Aug 1, 2026

Cancer Research UK

RRID:SCR_004041

Type: Tool

Proper Citation

Cancer Research UK (RRID:SCR_004041)

Resource Information

URL: <http://www.cancerresearchuk.org/>

Proper Citation: Cancer Research UK (RRID:SCR_004041)

Description: Cancer Research UK is UK's largest charity funding cancer research. Cancer Research UK is a registered charity in England and Wales (1089464) and in Scotland (SC041666). Registered as a company limited by guarantee in England & Wales No. 4325234.

Abbreviations: CRUK

Resource Type: institution

Resource Name: Cancer Research UK

Resource ID: SCR_004041

Alternate IDs: Wikidata: Q326079, Crossref funder ID: 501100000289, nlx_143542, grid.11485.39, ISNI: 0000 0004 0422 0975

Alternate URLs: <https://ror.org/054225q67>

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260725T190547+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Research UK.

No alerts have been found for Cancer Research UK.

Data and Source Information

Usage and Citation Metrics

We found 379 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Eldridge-Thomas BL, et al. (2025) The transmembrane protein Syndecan is required for stem cell survival and maintenance of their nuclear properties. PLoS genetics, 21(2), e1011586.

Moschopoulou E, et al. (2025) Development of ACT+: A Novel, Person-Centred Psychological Intervention Based on Acceptance and Commitment Therapy (ACT) to Improve Quality of Life in Patients Living With and Beyond Cancer. Health expectations : an international journal of public participation in health care and health policy, 28(2), e70237.

Kaur A, et al. (2025) Machine learning approach for optimizing usability of healthcare websites. Scientific reports, 15(1), 14450.

Little P, et al. (2025) Digital intervention (Renewed) to support symptom management, wellbeing, and quality of life among cancer survivors in primary care: a randomised controlled trial. The British journal of general practice : the journal of the Royal College of General Practitioners, 75(754), e357.

Sereesongsaeng N, et al. (2025) Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis. eLife, 14.

Erickson A, et al. (2025) Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers. PloS one, 20(1), e0316475.

Carr M, et al. (2024) Testing a faith-placed education intervention for bowel cancer screening in Muslim communities using a two-group non-randomised mixed-methods approach: Feasibility study protocol. PloS one, 19(3), e0293339.

Lei J, et al. (2024) Human papillomavirus genotype and cycle threshold value from self-samples and risk of high-grade cervical lesions: A post hoc analysis of a modified stepped-wedge implementation feasibility trial. PLoS medicine, 21(12), e1004494.

Bingham V, et al. (2024) Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications. Scientific reports, 14(1), 11361.

Ney A, et al. (2024) Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection. PLoS computational biology, 20(8), e1012408.

Hamilton-West KE, et al. (2024) Development of an implementation science informed "Test Evidence Transition" program to improve cancer outcomes. Frontiers in health

services, 4, 1328342.

Yarmolinsky J, et al. (2024) Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis. *EBioMedicine*, 100, 104991.

Gadsby JR, et al. (2024) The open to closed D-loop conformational switch determines length in filopodia-like actin bundles. *The Biochemical journal*, 481(24), 1977.

Bernacchia L, et al. (2023) Developing novel antimicrobials by combining cancer chemotherapeutics with bacterial DNA repair inhibitors. *PLoS pathogens*, 19(12), e1011875.

Farncombe KM, et al. (2023) Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy. *American journal of human genetics*, 110(10), 1616.

Tarantola A, et al. (2023) Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. *Journal of pharmaceutical policy and practice*, 16(1), 67.

Berman AG, et al. (2023) SLiDL: A toolbox for processing whole-slide images in deep learning. *PloS one*, 18(8), e0289499.

Puppo M, et al. (2023) MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness. *British journal of cancer*, 129(5), 754.

Barrott L, et al. (2023) Nurse and pharmacist systemic anti-cancer therapy review clinics and their impact on patient experience and care: A systematic review. *Journal of advanced nursing*, 79(2), 442.

Hamilton FW, et al. (2023) Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study. *PLoS medicine*, 20(1), e1004174.